Labcorp consensus stays steady, S&P 500 peer group frames the stock
30.06.2026 - 09:53:42 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:53.
Labcorp (US50540R4092) starts this Tuesday with a broadly stable view from Wall Street. The stock is part of the S&P 500 healthcare cohort, and investors focus on how its diagnostics and central lab services underpin earnings over the coming quarters.
What analyst consensus implies
Labcorp sits within a large US healthcare peer group that includes Quest Diagnostics and major hospital operators, giving analysts multiple comparables for margins and growth. A typical consensus picture for the stock combines long-term diagnostic volume trends, reimbursement assumptions, and cost controls in its large lab network.
In recent years, the shares have been covered by a broad mix of US and international houses, with ratings spread across Buy, Hold and occasional Sell stances as operating leverage and capital allocation policies shift. Price targets generally anchor on mid- to high-single-digit revenue growth and mid-teens operating margins for the core laboratory business.
How Labcorp fits the peer group
Within the S&P 500 healthcare segment, Labcorp is often compared with other service and tools providers rather than big pharma, as its revenue depends on test volumes, payer mix and contract wins. Investors watch how volumes trend across routine tests, specialized diagnostics and clinical trial support services.
The stock’s valuation tends to move with confidence in non-COVID testing growth, operating efficiency and the outlook for US and international healthcare spending. Capital returns via buybacks and dividends, alongside disciplined acquisitions, also feature prominently in analyst models when they assess total shareholder return.
All news and data on the Labcorp shares
More background, price information and corporate disclosures on Labcorp are available in the dedicated topic section and via the company’s investor relations pages.
The business behind the stock
Labcorp generates most of its revenue from diagnostic testing services, including routine blood work, specialized assays and pathology, ordered by physicians and hospitals. It also runs a sizeable clinical trial services unit, supporting pharmaceutical and biotech companies with central lab testing and related support.
Where the stock trades today
The Labcorp shares (US50540R4092) are listed on the NYSE under ticker LH. At the time of writing on 2026-06-30, 09:53, the current share price and market capitalization are determined by ongoing US trading and may differ from last night’s close.
Key data on the Labcorp shares
- Company: Laboratory Corporation of America Holdings
- ISIN: US50540R4092
- WKN: 895308
- Ticker: LH
- Trading venue: NYSE
- Price (as of 2026-06-30, 09:53): data based on latest NYSE trading in US dollars
- Market cap: latest available NYSE figure in US dollars (as of 2026-06-30)
- Sector / industry: Health Care Providers & Services / Diagnostics
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. All data and assessments are based on publicly available information believed to be reliable but not independently verified.
